A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
NotableStart date pushed from Oct 1, 2026 to Mar 31, 2027
Eligibility criteria expanded, about 62 words
Secondary endpoints: details revised at 7 of 16 entries
Collaborators: details revised at 1 of 1 entry
NotableStart date: Sep 1, 2026 to Oct 1, 2026v2
Study First Submitted
Notable: the plan changed
Endpoints
Primary
Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Timeframe: Up to approximately 6 years
Secondary (16)
Overall Survival (OS)
PFS as Assessed by Investigator per RECIST v1.1
Progression Free Survival 2 (PFS2)
Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)
Plasma Concentrations of R-DXd (Conjugated Antibody)
Show 11 moreShow less
Plasma Concentrations of Total Anti-Cadherin-6 (CDH6) Antibody
Plasma Concentrations of DXd Payload
Percentage of Participants Having Treatment-Emergent Antidrug Antibody (ADA)
CDH6 Protein Expression in Tumor Tissue as Determined by Immunochemistry Assay (Immunohistochemistry [IHC]) and Correlation with PFS and OS
Change From Baseline in Global Health Status/Quality of Life (QoL) Assessed by European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire Version 3.0 (EORTC QLQ-C30 v3.0)
Change From Baseline in Functional Sub-scales Scores Assessed by EORTC QLQ-C30 v3.0
Change From Baseline in Symptom Sub-scales Score Assessed by EORTC QLQ-C30 v3.0
Time to Deterioration (TTD) in Global Health Scale/QoL, Functioning and Symptoms as Measured by EORTC QLQ-C30 v3.0
Change From Baseline in Abdominal/Gastrointestinal (GI) Symptoms Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Ovarian Cancer Module (EORTC QLQ-OV28)
Change From Baseline in Attitude to Disease/Treatment Assessed by EORTC QLQ-OV28
TTD in Abdominal/GI Symptoms and Attitude to Disease/Treatment as Measured by EORTC QLQ-OV28
Arms and interventions
Arm 1: R-DXd Alone or R-DXd Combined with BevacizumabExperimental
Participants will be randomized to receive either R-DXd, intravenously (IV), every 3 weeks (Q3W) alone, or R-DXd IV along with bevacizumab 15mg/kg, IV, Q3W, on Day 1 of each 21-day cycle, until radiological disease progression according to RECIST v1.1 as assessed by BICR, unacceptable toxicity or other protocol-specified discontinuation criteria are met.
Arm 2: Bevacizumab Alone or ObservationActive comparator
Participants will be randomized to receive either bevacizumab 15 mg/kg, IV, Q3W, or Investigator's choice of observation until radiological disease progression as assessed by BICR or unacceptable toxicity or until other protocol-specified discontinuation criteria are met.